AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02315833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo capsule matching Acetium for oral administration.
Study NCT03018821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard - Fuzilizhong Decoction plus Jinkui Shenqi Bolus
Description: Fuzilizhong Decoction plus Jinkui Shenqi Bolus is one Chinese Medicine Formula for the TCM syndrome: Yang deficiency of spleen and kidney.
Study NCT03018821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advanced - Guifu Erxian Decoction
Description: Guifu Erxian Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yang deficiency of spleen and kidney.
Study NCT03018821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advanced - Supplemented Ganji Decoction
Description: Supplemented Ganji Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: internal blood stasis.
Study NCT00596284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)
Description: Cognitive behavioral therapy (CBT) will consist of 8 to 10 sessions over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day.
Study NCT00596284 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Following in-person meetings, participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months.
Study NCT00975650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasobol®
Description: Intra-nasal Testosterone (2 syringes), b.i.d.
Study NCT02081911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Volume Adductor Canal Block
Description: Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
Study NCT02081911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Volume Adductor Canal Block
Description: Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
Study NCT02081911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
Study NCT04063228 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple Skill Group
Description: will practice the following skills as needed: bed mobility, transfer, walking, and stairs.
Study NCT04063228 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex Skill Group
Description: The program will consist of interventions at the impairments level with an emphasis on core strengthening, functional lower extremity strengthening, balance and endurance training, and at the skill acquisition level. Participants will learn pre-running skills (walking, stairs with handrail, walking backward, walking over obstacles, walking on toes, stairs without handrail, bounding), running skills (force generation in vertical plane: hopping, alternate hopping, running in place in gravity minimized position and against gravity; force generation in horizontal plane: bounding, alternate bounding, open chain movement for swing phase, running) and post running skills (running forward, backward, sideways, skipping, hopping).
Study NCT03446313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movn Mobile App
Description: The Movn app will have each participant's personalized instructions for post-cardiac rehab integrated into it including medication reminders, physical activity prompts, educational materials, and patient-reported outcomes.
Study NCT03698929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Effect of Cholesterol - Egg Phase
Description: After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
Study NCT03698929 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Effect of Cholesterol - Non-Egg Phase
Description: After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
Study NCT01751373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal muscle activation therapy
Description: The proposed study uses a longitudinal, within-subject, pre/post intervention, cross-over design. All participants will complete each of 4 study phases (each 12 weeks long). These include: a) focal BTX injections in combination with either Standard Therapy or Optimal Muscle Activity Therapy; b) a three-month period where no treatment is given; c) focal BTX injections in combination either Standard Therapy or Optimal Muscle Activation Therapy; d) another three-month period where no treatment is given. The order of treatment phases will be counter-balanced across participants.
Study NCT00975650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androderm® (Positive Control)
Description: QD administration
Study NCT01751373 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Study NCT01442090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus will be administered orally at a 10 mg daily dose.
Study NCT01442090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: GDC-0980 will be administered orally at a 40 mg daily dose.
Study NCT00736450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00736450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT03466931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: Meals containing Milk and Milk
Study NCT00736450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00736450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00736450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00736450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT00736450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study NCT00736450 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies
Study NCT00736450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT00736450 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study NCT00736450 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative studies
Study NCT04288297 — intervention group
Intervention type: PROCEDURE
Intervention: distal minimally invasive chevron osteotomy
Description: With an electric motor-driven machine the resection of the medial eminence as well as a V-shaped osteotomy was performed in hallux valgus patients. Intraoperative fluoroscopy was used to identify the ideal osteotomy site and to control the Intervention. Fixation of the metatarsal head was achieved with a screw or with a K wire. Residual bone ridges were reamed and bone debris washed out.
Study NCT01442519 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bacillus Calmette-Guerin
Description: The BCG instillation consisted of 81 mg wet weight (10•2±9•0_108 colony-forming units) BCG Connaught substrain (ImmuCyst®, Alfa Wassermann SpA, Bologna, Italy). Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 120 min, followed by emptying of the bladder and removal of the catheter. The BCG-alone group is assigned one course of intravesical treatment per week for 6 weeks. Patients in the BCG-alone group who are disease-free 3 months after treatment are scheduled to receive monthly infusions of BCG for 10 months
Study NCT01442519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: electromotive mitomycin
Description: BCG instillation of 81 mg BCG Connaught-substrain, suspended in 50 mL bacteriostatic-free saline solution, retained for 120 min. Electromotive instillation: 40 mg mitomycin in 100 mL water infused intravesically and retained in the bladder for 30 min, while 20 mA for 30 min pulsed electric current is given externally. Patients assigned sequential BCG and EMDA MMC are assigned 1 course of treatment/week for 9 weeks: one cycle consisted of two BCG infusions and one mitomycin infusion (three cycles in total). Patients in the BCG-and-mitomycin group who are disease-free 3 months after treatment are scheduled to receive one infusion a month for 9 months: three cycles of mitomycin, mitomycin, and BCG (ie, six infusions of MMC and three of BCG).
Study NCT01017549 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Electronic brachytherapy (Axxent System)
Description: 3.4 Gy per fraction for 10 fractions for a total of 34 Gy.
Study NCT00872781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets
Study NCT00872781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets
Study NCT04383535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Convalescent SARS COVID-19 plasma
Description: Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
Study NCT04383535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single infusion of saline solution, in addition to standard care. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
Study NCT00654576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole
Description: patient will receive one of the seven study drugs (Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole) as the maintain treatment. the dose is flexible, is based on the study doctor's judgment.
Study NCT00654576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychosocial intervention
Description: the psychosocial interventions include psychoeducaiton, family intervention, skill training, and cognitive-behavioral therapy.
Study NCT04181073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Mesh Nebuliser
Description: Aerogen Device
Study NCT04666805 — intervention group
Intervention type: DRUG
Intervention: Tamoxifen
Description: 20 mg/d, oral administration
Study NCT04666805 — intervention group
Intervention type: DRUG
Intervention: Toremifene
Description: 60 mg/d, oral administration
Study NCT04666805 — intervention group
Intervention type: DRUG
Intervention: Anastrozole
Description: 1 tablet (1 mg) per day, oral administration
Study NCT01921283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS sensor attachment
Description: For double blind method, BIS sensors were attached to all patients, but only BIS-group was measured by the value. BIS monitor was pushed back toward the anesthesiologist so that the physician could not see it. 3 L/min of oxygen was delivered by a nasal cannula to all patients throughout the procedure. Blood pressure was recorded every 5 minutes and heart rate, peripheral oxygen saturation were measured continuously. For induction of sedation, propofol 1 mg/Kg and lidocaine 30mg was administered throughout IV line and immediately followed by continuous infusion of propofol 0.04-0.06 mg/Kg/min and remifentanil 0.05 mcg/Kg/min. The evaluation of sedation depth using OAA/S was performed at 1 minute after propofol administration, endoscopy insertion, submucosal inflation by 1:100000 epinephrine with indigocarmine, initial submucosal dissection and when the patient had restlessness or coughing additively.
Study NCT01921283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no- BIS sensor attachment
Study NCT01751360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Study NCT03612544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (Vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study NCT03612544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study NCT03027869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: 15 minute anodal stimulation 1.5mA
Study NCT03027869 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: 15 minute anodal stimulation 1.5mA
Study NCT03649139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual immunotherapy drops
Description: artemisia annua (sweet sagewort) allergen extract drops
Study NCT03649139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drops
Description: sublingual placebo drops
Study NCT01352767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InsuPad
Description: Heating pad
Study NCT00184067 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Montanide ISA 51
Study NCT00184067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51
Study NCT02427893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cobimetinib
Description: A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.
Study NCT03655080 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Using the View Ray System
Study NCT03655080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: * Dose 15 mg/m\^2~* Should be administered by IV over 30 minutes
Study NCT04308408 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guideline Daily Amounts
Description: All food items displayed the corresponding GDA label in the lower left corner of the front of the package.
Study NCT04308408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Traffic Light
Description: All food items displayed the corresponding MTL label in the lower left corner of the front of the package.
Study NCT04308408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warning Labels
Description: Food products were labeled with High in labels In the lower left corner of the front of the package. In total, 37 of the 60 food products in the shopping site did not display a WL.
Study NCT04308408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants viewed a short (less than 1 min) video explaining how to interpret the label.
Study NCT04308408 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: Participants viewed a short (less than 1 min) video explaining how to interpret the label.
Study NCT03458988 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Blood-pressure measuring (Nellcor™ Adult SpO2 Sensor)
Description: Data will be acquired for 10 minutes with a reusable off the shelf adult SpO2 sensor. The Nellcor™ Adult SpO2 Sensor, model DS-100A, is indicated for use when continuous noninvasive arterial oxygen saturation and pulse rate monitoring are required for patients weighing greater than 40 kg.
Study NCT04666805 — intervention group
Intervention type: DRUG
Intervention: Letrozole
Description: Adjuvant therapy with letrozole for 5 years or until the disease relapses. Patients who have received tamoxifen adjuvant therapy for 5 years should continue to take Letrozole until the disease relapses. The recommended dose of Letrozole tablets is one 2.5 mg tablet administered once a day, without regard to meals. For patients with advanced breast cancer, treatment with Letrozole should continue until tumor progression is confirmed. Patients with liver and/or renal dysfunction (creatinine clearance rate ≥ 10 mL/min) do not need to adjust the dosage.
Study NCT04666805 — intervention group
Intervention type: DRUG
Intervention: Exemestane
Description: The recommended dose of Exemestane for adult and older patients with early and advanced breast cancer is one 25 mg tablet administered orally once a day after a meal. After 2-3 years of tamoxifen treatment, patients with early breast cancer should continue to use Tamoxifen in the case of no recurrence or contralateral breast cancer, until the completion of 5-year sequential adjuvant therapy with tamoxifen and exemestane. Patients with advanced breast cancer should continue to take Exemestane until the tumor progresses.
Study NCT03275519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomization to not receive prophylactic antibiotics after surgery.
Description: No antibiotics were ordered after surgery.
Study NCT03275519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomization to receive prophylactic antibiotics after surgery
Description: In general, the antibiotic given is a combination sulfamethoxazole/ trimethoprim oral suspension (2-3 mg trimethoprim/kg by mouth once a day); or if indicated, nitrofurantoin (1mg/kg by mouth once daily). All subjects did not receive intraoperative antibiotics.
Study NCT01017692 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: MRI of lumbar spine for subjects presenting with spinal stenosis symptoms
Study NCT02278380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low GI Standard Breakfast
Description: Low GI Standard Breakfast
Study NCT02278380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medium GI Standard Breakfast
Description: Medium GI Standard Breakfast
Study NCT02278380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enfamama A+
Description: Nutritional pregnant milk supplement
Study NCT02278380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucerna Triple Care
Description: Nutritional product for diabetics
Study NCT02278380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dumex Precima
Description: Pregnant and lactation women milk powder
Study NCT02427893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemurafenib
Description: A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma
Study NCT01425281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
Description: XIENCE implantation in the treatment of coronary artery disease.
Study NCT01425281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
Description: ABSORB BVS implantation in the treatment of coronary artery disease.